Haleon's (HLN) Underweight Rating Reiterated at JPMorgan Chase & Co.

Haleon (LON:HLN - Get Free Report)'s stock had its "underweight" rating reissued by research analysts at JPMorgan Chase & Co. in a note issued to investors on Friday,London Stock Exchange reports.Separately, Royal Bank Of Canada restated a "sector perform" rating and issued a GBX 370 ($4.89) target price on shares of Haleon in a report on Thursday.Read Our Latest Report on HLNHaleon Stock PerformanceShares of LON HLN opened at GBX 366.53 ($4.84) on Friday. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The stock has a market capitalization of £33.08 billion, a price-to-earnings ratio of 30.83, a PEG ratio of 1.49 and a beta of 0.19. The stock's fifty day simple moving average is GBX 382.62 and its 200 day simple moving average is GBX 385.08. Haleon has a 52-week low of GBX 346.10 ($4.57) and a 52-week high of GBX 419.50 ($5.54). Haleon (LON:HLN - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported GBX 8.90 ($0.12) earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, sell-side analysts forecast that Haleon will post 19.5033282 earnings per share for the current fiscal year. Insider Activity at HaleonIn other news, insider Dawn Allen sold 64,329 shares of the company's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of GBX 376 ($4.97), for a total value of £241,877.04 ($319,520.53). Also, insider Marie-Anne Aymerich purchased 21,300 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The shares were acquired at an average price of GBX 405 ($5.35) per share, for a total transaction of £86,265 ($113,956.41). Corporate insiders own 10.74% of the company's stock. Haleon Company Profile (Get Free Report)Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.Recommended StoriesFive stocks we like better than HaleonWhat Do S&P 500 Stocks Tell Investors About the Market? Newmont's Financial Strength Sets a High Bar for Gold MinersGolden Cross Stocks: Pattern, Examples and Charts Golden Cross Alert: 3 Stocks With Serious Upside Potential3 Stocks to Consider Buying in OctoberBig Beat, Bigger Plans: AEP Stock Powers Up on Data Center BoomThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Haleon Right Now?Before you consider Haleon, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.While Haleon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here